CR MEDICAL (01515): Fang Xin appointed as non-executive director.
China Resources Healthcare (01515) announced that starting from March 11, 2026: (1) Ms. Ge Lu resigned as a non-executive director and a member of the remuneration committee; and (2) Mr. Fang Xin was appointed as a non-executive director and a member of the remuneration committee.
CR MEDICAL (01515) announced that, starting from March 11, 2026: (1) Ms. Ge Lu resigned as a non-executive director and member of the remuneration committee; and (2) Mr. Fang Xin was appointed as a non-executive director and member of the remuneration committee.
Related Articles
Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.
East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.
SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.
Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.
East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.
SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
